{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:57:42Z","timestamp":1785549462084,"version":"3.56.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.clml.2015.09.006","type":"journal-article","created":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T17:40:45Z","timestamp":1442857245000},"page":"803-810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment Outcomes in CML Patients Treated With Tyrosine Kinase Inhibitors at a Tertiary Teaching Hospital in South Africa"],"prefix":"10.1016","volume":"15","author":[{"given":"Gerhard","family":"Sissolak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Badenhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janami","family":"Steenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vernon","family":"Louw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"Schnugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Willem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.09.006_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0002-9343(77)90124-3","article-title":"Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte\/macrophage","volume":"63","author":"Fialkow","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2015.09.006_bib2","series-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","first-page":"32","article-title":"Chronic myelogenous leukemia BCR-ABL1 positive","author":"Vardiman","year":"2008"},{"key":"10.1016\/j.clml.2015.09.006_bib3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.clml.2015.09.006_bib4","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.09.006_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.09.006_bib6","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.09.006_bib7","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood.V99.5.1527","article-title":"A\u00a0randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia","volume":"99","author":"Baccarani","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.09.006_bib8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.seminhematol.2010.06.003","article-title":"Current status of imatinib as frontline therapy for chronic myeloid leukemia","volume":"47","author":"Marin","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2015.09.006_bib9","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.09.006_bib10","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.09.006_bib11","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1200\/JCO.2008.18.7740","article-title":"HLA-identical sibling compared with 8\/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia","volume":"27","author":"Arora","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.09.006_bib12","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.09.006_bib13","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2007-09-110189","article-title":"Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods","volume":"111","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.09.006_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3816\/CLK.2008.n.036","article-title":"Chronic myeloid leukemia: a clinicoepidemiologic and therapeutic description of a single institution in Mexico City","volume":"2","author":"Aguayo","year":"2008","journal-title":"Clin Leuk"},{"key":"10.1016\/j.clml.2015.09.006_bib15","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/cncr.22498","article-title":"Treatment of chronic myeloid leukemia in the imatinib era","volume":"109","author":"Aziz","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2015.09.006_bib16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s12185-012-1073-2","article-title":"Chronic myeloid leukaemia and human immunodeficiency virus (HIV) infection","volume":"95","author":"Webb","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2015.09.006_bib17","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.leukres.2012.07.012","article-title":"Human immunodeficiency virus infection and chronic myeloid leukemia","volume":"36","author":"Patel","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.09.006_bib18","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/bmj.313.7070.1445","article-title":"Informed consent in human experimentation before the Nuremberg code","volume":"313","author":"Vollmann","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2015.09.006_bib19","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.09.006_bib20","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.09.006_bib21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1046\/j.1365-2141.2002.03705.x","article-title":"Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia","volume":"118","author":"Wang","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.09.006_bib22","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/leu.2008.225","article-title":"A\u00a0population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials","volume":"22","author":"Lucas","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.09.006_bib23","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/10428190701824585","article-title":"Imatinib mesylate in early chronic phase chronic myeloid leukemia: experience from a developing country","volume":"49","author":"Rajappa","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.09.006_bib24","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u201creal-time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia \u2013 A Europe Against Cancer Program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.09.006_bib25","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the ATP binding region of BCR\/ABL in CML and Ph-positive ALL patients who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.09.006_bib26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.09.006_bib27","first-page":"185","article-title":"Asymptotically efficient rank invariant test procedures","volume":"135","author":"Peto","year":"1972","journal-title":"J\u00a0R Stat Soc"},{"key":"10.1016\/j.clml.2015.09.006_bib28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4102\/sajhivmed.v13i3.125","article-title":"Guidelines for antiretroviral therapy in adults","volume":"13","author":"Meintjes","year":"2012","journal-title":"S\u00a0Afr J HIV Med"},{"key":"10.1016\/j.clml.2015.09.006_bib29","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jnci\/djk150","article-title":"Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells","volume":"99","author":"Jiang","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2015.09.006_bib30","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER cancer statistics review, 1975-2009 (Vintage 2009 populations). Available at: http:\/\/seer.cancer.gov\/csr\/1975_2009_pops09. Accessed August 17, 2015."},{"key":"10.1016\/j.clml.2015.09.006_bib31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.canep.2013.01.002","article-title":"Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries","volume":"37","author":"Mendizabal","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.clml.2015.09.006_bib32","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","article-title":"Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy","volume":"97","author":"Pemmaraju","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.09.006_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00277-013-1937-4","article-title":"Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV","volume":"93","author":"Kalmanti","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2015.09.006_bib34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/annonc\/mdu490","article-title":"GIMEMA CML Working Party: differences among young adults, adults and elderly chronic myeloid leukemia patients","volume":"26","author":"Castagnetti","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2015.09.006_bib35","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3109\/10428194.2010.507416","article-title":"Response assessment of patients with chronic myeloid leukemia receiving imatinibmesylate (Glivec) therapy: experience from a single center in a developing country","volume":"51","author":"Medhi","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.09.006_bib36","unstructured":"Wikipedia. HIV\/AIDS in South Africa. Available at: http:\/\/en.wikipedia.org\/wiki\/HIV\/AIDS_in_South_Africa. Accessed August 17, 2015."},{"key":"10.1016\/j.clml.2015.09.006_bib37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2009.012781","article-title":"Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"95","author":"Milojkovic","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.09.006_bib38","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"De Lavallade","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.09.006_bib39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/leu.2010.215","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"25","author":"Jabbour","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.09.006_bib40","doi-asserted-by":"crossref","first-page":"e004266","DOI":"10.1136\/bmjopen-2013-004266","article-title":"Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort","volume":"4","author":"Smith","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.clml.2015.09.006_bib41","doi-asserted-by":"crossref","unstructured":"Deininger M, O'Brien SG, Guilhot F, et\u00a0al. International Randomized study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Annual Meeting Abstracts 2009; 114 abstract 1126.","DOI":"10.1182\/blood.V114.22.1126.1126"},{"key":"10.1016\/j.clml.2015.09.006_bib42","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2009.021154","article-title":"Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group","volume":"95","author":"Cervantes","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.09.006_bib43","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00277-011-1359-0","article-title":"Good adherence to imatinib therapy among patients with chronic myeloid leukemia\u2013a single-center observational study","volume":"91","author":"J\u00f6nsson","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2015.09.006_bib44","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clml.2011.10.004","article-title":"Managing chronic myeloid leukemia: a coordinated team care perspective","volume":"12","author":"Holloway","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2015.09.006_bib45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.09.006_bib46","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.09.006_bib47","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015012884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015012884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:31Z","timestamp":1761870391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015012884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S2152265015012884"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.09.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Outcomes in CML Patients Treated With Tyrosine Kinase Inhibitors at a Tertiary Teaching Hospital in South Africa","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}